Literature DB >> 27511285

Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer.

Maria C Russell1.   

Abstract

Gastric cancer remains a significant worldwide health concern. While surgery is required for cure, all but the earliest of cancers will require multimodality therapy. Chemotherapy and chemoradiation in the neoadjuvant and adjuvant settings have shown to improve overall survival, but the sequencing of treatment is controversial. As healthcare expenses surge, it is increasingly important to impart value to these treatments. This review will look at the intersection of effective treatment and costs for gastric cancer. J. Surg. Oncol. 2016;114:296-303.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  gastric cancer; neoadjuvant gastric cancer; value gastric

Mesh:

Year:  2016        PMID: 27511285     DOI: 10.1002/jso.24293

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma.

Authors:  M L Sánchez de Molina; C Díaz Del Arco; P Vorwald; D García-Olmo; L Estrada; M J Fernández-Aceñero
Journal:  Clin Transl Oncol       Date:  2017-06-26       Impact factor: 3.405

2.  Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.

Authors:  Hai-Liang Li; Jin-Rong Qu; Jing Li; Liang-Liang Yan; Hong-Kai Zhang; Yi Wang; Shu-Ning Xu
Journal:  Abdom Radiol (NY)       Date:  2022-08-02

3.  Radical Gastrectomy: Still the Cornerstone of Curative Treatment for Gastric Cancer in the Perioperative Chemotherapy Era-A Single Institute Experience over a Decade.

Authors:  Harsh Kanhere; Raghav Goel; Ben Finlay; Markus Trochsler; Guy Maddern
Journal:  Int J Surg Oncol       Date:  2018-01-14

4.  Identification of UAP1L1 as tumor promotor in gastric cancer through regulation of CDK6.

Authors:  Jing Qi; Sheng Liu; Weihang Liu; Gaoqiang Cai; Guoqing Liao
Journal:  Aging (Albany NY)       Date:  2020-04-20       Impact factor: 5.682

5.  Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer.

Authors:  Viacheslav Chubenko; Gamzat Inusilaev; Evgeny Imyanitov; Vladimir Moiseyenko
Journal:  BMJ Case Rep       Date:  2020-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.